The inhibiting effect of alpha-based TARE on embolized vessels and neovascularization

Qianqian Tong1,2†, Rou Li2†, Ruizhi Wang3, Changjing Zuo2, Danni Li2, Guorong Jia2, Ye Peng2, Xiaohong Li2, Jian Yang2, Shuai Xue1, Qingyun Bai1* and Xiao Li2,4*

1School of Chemistry and Bioengineering, Yichun University, Yichun, Jiangxi, China, 2Department of Nuclear Medicine, Changhai Hospital, Naval Medical University, Shanghai, China, 3Department of Radiology, Huadong Hospital, Fudan University, Shanghai, China, 4Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, China

Transarterial embolization (TAE) is a personalized technology that offers precise delivery of chemotherapeutic drugs or selective internal radiation therapy for hepatocellular carcinoma (HCC). Beta-emitting radionuclide embolisms for TAE (β-based TARE) are commonly used in the clinic via inducing biochemical lethality on tumor cells, while alpha-emitting radionuclides-based embolisms for TAE (α-based TARE) are still under study. The feeding artery plays a key role in tumor growth, metastasis, and recurrence. In this research, the auricular central arteries (ACAs) of rabbits were embolized with silk fibroin-based microspheres (SFMs) or SFMs integrated with α(Ra-223) or β(I-131) radionuclides to investigate the influence on vessels. TARE-induced tissue necrosis and the following neovascularization were measured by pathological analysis and 68Ga-DOTA-RGD PET/CT. The results showed that, compared to I-131, Ra-223 enhanced the growth inhibition of human hepatoma cells Huh-7 and induced more DNA double-strand breaks in vascular smooth muscle cells. Unlike β-based TARE, which mainly led to extensive necrosis of surrounding tissues, α-based TARE induced irreversible necrosis of a limited area adjacent to the embolized vessels. RGD PET revealed the inhibition on neovascularization in α-based TARE (SUVmax = 0.053 ± 0.004) when compared with normal group (SUVmax = 0.099 ± 0.036), the SFMs-lipiodol group (SUVmax = 0.240 ± 0.040), and β-based TARE (SUVmax = 0.141 ± 0.026), owing to the avoidance of the embolism-induced neovascularization. In conclusion, α-based TARE provided a promising strategy for HCC treatments via destroying the embolized vessels and inhibiting neovascularization.
1 Introduction

Liver cancer is a major global health challenge, and hepatocellular carcinoma (HCC) is the most common (90%) type of primary liver cancer (Llovet et al., 2021). As a treatment with precise delivery of radioactive nuclides to the tumorous feeding artery, transarterial radioembolization (TARE) delivers therapeutic isotopes targeting the tumor in patients with unresectable hepatic malignancy (Habib et al., 2015; Bruix et al., 2016). Recently, with the development of nuclear technology and innovation of theranostic equipment, a number of radioactive microspheres and particles for TARE have become available.

So far, three types of beta-emitting radionuclide embolisms for TARE (β-based TARE) have been applied in the clinic. These β-emitting radionuclides generate β-rays with linear energy (0.1–2.2 MeV) to produce reactive oxygen species (ROS), leading to the mitochondria-related cellular apoptosis or damage to the single-strand DNA of cells (Aghelvian et al., 2017; King et al., 2021). The range of β-emitting is over 1 mm, an effective range to cover most solid tumors when beads are embolized in the peripheral artery. In the clinic, yttrium-90 (Y-90) microspheres, including TheraSpheres and SIR-Spheres, have already been applied in unresectable HCC or unresectable liver metastases of colorectal cancer (Edeline et al., 2015). Recently, a type of holmium-166 (Ho-166) microspheres named QuiremSpheres, which were developed with biodegradable poly-l-lactic acid-based microspheres containing Ho-166, have been approved to treat unresectable liver cancer (Reinders et al., 2019). Another extensively used β-emitting radionuclide is iodine-131 (I-131), which has several advantages, including economic feasibility and easy securement (Fujiiwara, 2016). In detail, I-131 has a half-life of 8.06 d (t1/2 = 8.06 d) and emits β particles of maximum energy of 0.6 MeV with a 2.3 mm maximum range in tissue (Mies et al., 1981), which could penetrate the embolized arterial walls and reach the boundary of tumorous tissues (Li et al., 2021). Hence, β-emitting radionuclides like Y-90, Ho-166, and I-131 are commonly developed or being developed for β-based TARE.

Different from β-emitting radionuclides, α-emitting radionuclides are among the most radiotoxic of all radionuclides. Although the radionuclides (such as iodine-125) with Auger electrons are of nuclear toxicity, the requirements for entrance into cells and approaching the cell nucleus limit the opportunity to translate these properties into clinical therapies. Usually, α nuclides permit a short range of radiation of less than 100 μm (Kratochwil et al., 2014), but the linear energy is 100–1,000 times greater than conventional β-emitting radionuclides (Sgouros, 2008). Along the emitting track in vivo, α-particles could emit thousands of ion pairs with radiation from enormously higher linear energy (4–9 MeV) to deposit on and break the double-strand DNA (Heskamp et al., 2017). Therefore, α-emitting radionuclides irreversibly accelerate the death of the exposed cells. For example, radium-223 (Ra-223) has a half-life of 11.43 d (t1/2 = 11.43 d), and four emissions of α-particles are generated during each decay. These particles predominately break double-strand DNA, which accounts for the irreversible cell damage (Pandit-Taskar et al., 2014; Roobol et al., 2020). In addition to cellular death, embolization-induced neovascularization is the first concern in controlling recurrence and metastasis. However, in the application of alpha-emitting radionuclide-based embolisms for transarterial embolization (α-based TARE), the systemic influence of the α-emitter in the whole procedure of embolization, especially its effect on the embolized vessels and the following vascular remodeling, was not understood.

Until now, fewer α-emitting radionuclides have been used in TARE. This present study aims to determine the principles of α-based TARE, especially the effect of radiation on the embolized artery and surrounding tissues. Ra-223 was chosen as the representative radionuclide in exploring α-based TARE, and I-131 served as a comparison with different therapeutic effects (Figure 1). Silk fibroin microspheres (SFMs) offer the characteristics of relatively good dispersion stability, biodegradability, biocompatibility, and low cytotoxicity (Sun et al., 2018; He et al., 2020), and the feasibility of radionuclide-labeled SFMs for TARE to treat HCC has been proven (Wu et al., 2022). In this study, we compared the ability of I-131 and Ra-223 to induce apoptosis at the cellular level, the inhibition effects on tumor cell growth, and the induction of γ-H2AX in vascular smooth muscle cells (VSMCs). SFMs combined with Ra-223 or I-131 were injected into the auricular central artery (ACA) of rabbits, where the radionuclides served as the unique variable. Single photon planar imaging was used to quantify the efficiency of

FIGURE 1
The schematic radiation process and the main damage approaches of β-based TARE and α-based TARE. The shaded area represents the radiation coverage area.
embolization, and the subsequent damage to the appearance and pathological section of the ear were recorded. Functional imaging of neovascularization was performed using positron emission tomography/computed tomography (PET/CT) imaging with gallium-68-labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugated with arginine-glycine-aspartate (68Ga-DOTA-RGD) post TARE, and the specific findings were verified with pathological analysis.

2 Materials and methods

2.1 Materials and animals

Na131I was purchased from Shanghai XinKe Pharmaceutical Co., Ltd. 223RaCl₂ was purchased from the Institute for Energy Technology. The operation related to the above agents was performed in a hot cell. Ethiodized poppyseed oil injection was purchased from Jiangsu HengRui Medicine Co., Ltd. Silk fibroin microspheres (about 150.61 ± 10.39 μm in diameter, controlled by steel screens) were purchased from Suzhou MeiLun Biotechnology Co., Ltd. The TdT-mediated dUTP nick-End Labeling (TUNEL) kit was purchased from KeyGEN Biotechnology Co., Ltd. 223RaCl₂ was purchased from the Institute for Energy Technology. The operation related to the above agents was performed in a hot cell. Ethiodized poppyseed oil injection was purchased from Jiangsu HengRui Medicine Co., Ltd. Silk fibroin microspheres (about 150.61 ± 10.39 μm in diameter, controlled by steel screens) were purchased from Suzhou MeiLun Biotechnology Co., Ltd. The annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis kit was purchased from BD Bioscience. A cell counting kit-8 (CCK-8) was purchased from Ailingfei Biotechnology Co., Ltd., and kept under a specific pathogen-free condition at the laboratory animal center. This research was approved and guided by the Ethics Committee of Naval Medical University (Approval No. 1207050662).

2.2 Cell culture

Primary mouse VSMCs were isolated from C57BL/6 mice as previously described (Chamley-Campbell et al., 1979). VSMCs were grown to confluence in DMEM medium supplemented with 10% FBS and 1% penicillin-streptomycin. Huh-7 cells were cultured in DMEM containing 10% FBS at 37°C in 5% CO₂.

2.3 Flow cytometry

VSMCs and Huh-7 cells at a density of 10⁵ cells per sample were incubated with I-131 (1 mCi) or Ra-223 (1 μCi) for 24 h at 37°C, respectively. Post incubation, the cells were washed twice with cold PBS and then stained using the annexin V-FITC/PI apoptosis kit, followed by flow cytometric analysis. The percentage of apoptosis was corrected for background levels found in the corresponding untreated controls. The percentage of cells undergoing apoptosis was defined as the sum of early apoptosis (annexin V-positive and PI-negative) and late apoptosis (annexin V-positive and PI-positive) cells. Necrotic cells of VSMCs and Huh-7 cells were defined as the percentage of annexin V-negative and PI-positive cells. Three independent experiments were performed, and the values of apoptotic percentages were presented as the mean ± SD.

2.4 Cell viability and γ-H2AX activation assays

The cell viability assay was performed on tumor cells using CCK-8. Huh-7 cells were seeded into 96-well culture plates at a density of 1 × 10⁴ cells per well in 100 μl culture medium and cultured overnight at 37°C. Three duplicate wells were set up for each group. The cells were then exposed to 1-131 (100 μCi) or Ra-223 (0.1 μCi) for 24 h, then 10 μl CCK-8 solution was added to each well. After incubating for 4 h at 37°C in 5% CO₂, absorbance at 450 nm was measured using a microplate reader.

For the γ-H2AX assay, VSMCs were seeded into 96-well culture plates at a density of 1 × 10⁵ cells per well and incubated overnight at 37°C. VSMCs were treated with 1-131 (100 μCi) or Ra-223 (0.1 μCi) for 24 h. Subsequently, the treated VSMCs were fixed, permeabilized, and stained with anti-γ-H2AX following the γ-H2AX ELISA kit protocol. The induced concentration of γ-H2AX was quantified on the basis of absorbance at 450 nm.

2.5 Preparation of embolism and radiopharmaceuticals

To make SFMs-lipiodol TAE, 50 μg SFMs were added into 1 ml 0.9% saline to obtain an SFMs suspension. Afterward, 2 ml ethiodized poppyseed oil injection was added to the SFMs suspension. The SFMs-lipiodol suspension was further aspirated and blown with a pipette and then sonicated for 1 minute to ensure the homogeneous dispersion of microspheres.

To make 131I-SFMs-lipiodol TARE, 1 ml Na131I (6.6 MBq) was mixed with 50 μg SFMs and vibrated for 10 min to increase physical adsorption between I-131 and SFMs. The adsorption rate was evaluated with thin-layer chromatography (TLC) with a radioactive detector. Glass microfiber chromatography paper impregnated with silica gel was used as the stationary phase, and saline was used as the mobile phase. The free I-131 was removed by centrifugation if the adsorption rate was less than 90%. Then, 2 ml ethiodized poppyseed oil was added to 131I-SFMs to obtain the suspension of 131I-SFMs-lipiodol. The
β-based TARE of each ACA used 1.1 MBq/0.5 ml ¹³¹I-SFMs-lipiodol.

To make ²²³Ra-SFMs-lipiodol TARE, 1 ml Ra-223 (6.6 kBq) was mixed with 50 μg SFMs and vibrated for 10 min to increase the physical adsorption of Ra-223 to SFMs. The quality control and purification were the same as 1-131. After that, 2 ml ethiodized poppyseed oil was added to the mixture and mixed as described above. The ²²³Ra-SFMs-lipiodol was suspended, and 1.1 kBq/0.5 ml was used for the α-based TARE of each ACA. ⁶⁶⁸Ga⁺ was acquired in the form of ⁶⁶⁸GaCl₃ from a⁶⁶⁸Ge/⁶⁸Ga generator by elution with 0.1 M HCl and then labeled to the integrin-targeted DOTA-RGD in house following the protocols. Quality control of ⁶⁶⁸Ga-DOTA-RGD was performed to guarantee the radiochemical purity >90%. The injected dosage of each rabbit was set as 7.4 MBq/kg body weight.

2.6 Radioembolization of auricular central arteries

In consideration of the visibility of ACAs, the strategy of ACA embolization was chosen to verify α-TARE (Li et al., 2021). ACA embolization of 12 rabbits was performed to evaluate the differential radiation damage to the artery and surrounding tissues. Before embolization, the ears of New Zealand rabbits were shaved and cleaned. Afterward, the rabbits (n = 3 for each group) were divided into four groups: a normal group, an SFMs-lipiodol group, a ¹³¹I-SFMs-lipiodol group, and a ²²³Ra-SFMs-lipiodol group. The rabbits were anesthetized under 3% (v/v) isoflurane. Before embolization, the ears of New Zealand rabbits were anesthetized under 3% (v/v) isoflurane. In addition, ears were stretched away from the body to avoid signal interference from other organs. The SPECT/CT scan was equipped with a high-resolution collimator, and the acquisition of planar pictures was performed in 5 min with matrix = 256 × 256 and zoom = 1.

Radiation from ¹³¹I-SFMs-lipiodol was measured by a Radiation Alert® inspector to quantify the embolization efficiency. The radiation from the whole body and the body except for the embolized ear was measured at 0, 36, 72, and 120 h post embolization. Embolized dosage (ED) was used in this study to represent the results, which was similar to “ID” in SPECT/CT. The time-dependent residuals in the embolized ear were calculated, and the ratio of the embolization in the ear to the whole body and the residual percentage of embolization in the ear are presented as line charts.

2.8 ⁶⁸Ga-DOTA-RGD PET/CT imaging

⁶⁸Ga-labeled arginine-glycine-aspartate peptides were regarded as PET tracers for angiogenesis imaging because RGD is specific toward the integrin αvβ₃ that is excessively expressed during neovascularization (Parihar et al., 2020). To compare the state of the neovascularization of ears after embolization in each group, a ⁶⁸Ga-DOTA-RGD PET/CT scan was performed at 4 days post-embolization. About 7.4 MBq/kg of ⁶⁸Ga-DOTA-RGD were administrated through the ear vein, and PET/CT images were acquired 45 min later. The spatial resolution of the PET/CT scanner (Biograph 64; Siemens) was 1 mm with CT (120 kV, 35 mA). In addition, the reconstruction resolution of CT was 1 mm by the postprocessing workstation TureD system. The tracer uptake of ⁶⁸Ga-DOTA-RGD was presented as the maximum standardized uptake value (SUV_max).

2.9 Histopathological examination

After 7 days post-embolization, all rabbits were sacrificed with excessive anesthesia. All ears were harvested, and the selected tissues mainly included the auricular artery and surrounding tissues, which were fixed and preserved in 10% neutral buffered formalin for 48 h. Thereafter, the fixed tissues were dehydrated, transparentized, embedded in paraffin, and longitudinally cut into 4-μm thick slices. Slices were stained with hematoxylin-eosin (H&E) and TUNEL and then photographed under a microscope equipped with optical and fluorescent lenses.

2.10 Statistical analysis

The values of SUV_max were described as the mean ± standard deviation (SD). Comparisons were performed using an unpaired
Analyses of histopathological examination were performed using ImageJ software.

### 3 Results

#### 3.1 Cell damage by radiation

Apoptosis and necrosis were the main consequence of radiation. The effects of 24 h radiation of radionuclides on Huh-7 and VSMCs were examined using flow cytometry on apoptosis. As shown in Figure 2A, compared with the normal group, apoptotic percentages were elevated in Huh-7 cells and VSMCs after the treatment of I-131 and Ra-223. Compared with normal Huh-7 cells (20.20% ± 0.70%), the percentage of apoptotic Huh-7 cells increased to 29.33% ± 0.08% after treatment with I-131 and 39.93% ± 0.03% after treatment with Ra-223. Compared with normal VSMCs (31.15% ± 1.38%), the percentage of apoptotic VSMCs increased to 79.41% ± 1.41% after treatment with I-131 and 88.88% ± 0.29% after treatment with Ra-223. Although I-131 and Ra-223 both induced apoptosis, the effects of Ra-223 in Huh-7 cells at the late stage of apoptosis and in VSMCs at the early stage of apoptosis were more obvious than I-131. In addition, the percentage of necrotic Huh-7 cells increased to 7.81% ± 0.26% after treatment with I-131 and 9.87% ± 0.21% after treatment with Ra-223. The percentage of necrotic VSMCs increased to 4.22% ± 0.31% after treatment with I-131 and 4.13% ± 0.30% after treatment with Ra-223.

In order to determine the influences of treatment on tumorous cell viability, the cellular viability of Huh-7 cells co-incubated with I-131 or Ra-223 for 24 h was examined via the CCK-8. Compared to the control group, treatments with I-131 and Ra-223 signally inhibited Huh-7 cell viability (Figure 2B), and treatment with Ra-223 was more effective in inhibiting Huh-7 cell proliferation.
Compared to the DNA strand breakage caused by the I-131-induced γ-H2AX (1.89 ± 0.05 μg/ml), the treatment of Ra-223 further increased γ-H2AX expression levels (5.05 ± 0.05 μg/ml) (Figure 2C), creating a more thorough lethality.

3.2 Radioembolization of auricular central arteries

$^{131}$I-SFMs and $^{223}$Ra-SFMs were successfully synthesized via the adsorption capacity of protein in silk fibrin. Although the physical adsorption was of relatively low stability, this approach was the most effective way of establishing the unbiased protocol to only evaluate the influence of nuclides, regardless of confounding factors, such as the chemical modification and labeling method. In addition, the $^{68}$Ga-DOTA-RGD synthesized in house met the quality control criteria of acid-base property (pH = 4), radiochemical purity (>95%), and solubility (clear and no undissolved substance). The specificity activity was adjusted to around 37 MBq/μg precursor.

As time progressed, progressive changes in skin color and appearance of the rabbit ears were observed in the embolization groups. As shown in Figure 3, the ACAs, auricular veins, and terminal branches of vessels were immediately pale after injection, owing to the blockage of blood flow. After embolization for 1 day, the vascular color in the ACA changed to purple in the embolization groups (the SFMs-lipiodol group, the $^{131}$I-SFMs-lipiodol group, and the $^{223}$Ra-SFMs-lipiodol group). Distal vessels and tissues around the embolized arteries became maroon in the $^{131}$I-SFMs-lipiodol group. By comparison, the surrounding tissues remained normal during the super early period of embolization in the $^{223}$Ra-SFMs-lipiodol group. On the third day after embolization, the congestive edema of ears in the SFMs-lipiodol group emerged, and then necrosis occurred in a portion of the tissue. Extensive necrosis and shrinkage of ears were observed in the $^{131}$I-SFMs-lipiodol group. Comparably, no recanalization of the ACA occurred, and tissues around arteries only slightly turned purple in the $^{223}$Ra-SFMs-lipiodol group at 3 days post-embolization. Significant changes could be seen in the $^{223}$Ra-SFMs-lipiodol group from the fifth to the seventh day post-embolization. The distal tissue supplied by the embolized vessel became black, stiff, and twisted, while the adjacent and proximal tissues showed no damage. Conversely, some

| pretreatment | treatment | 1 d | 3 d | 5 d | 7 d |
|--------------|-----------|-----|-----|-----|-----|
| normal | | | | | |
| SFMs-lipiodol | | | | | |
| $^{131}$I-SFMs-lipiodol | | | | | |
| $^{223}$Ra-SFMs-lipiodol | | | | | |

**FIGURE 3**
The appearance of pre-embolization rabbit ears, immediately post treatment with SFMs-lipiodol, $^{131}$I-SFMs-lipiodol and $^{223}$Ra-SFMs-lipiodol, and at 1, 3, 5, and 7 days post-embolization.
normal non-necrotic tissues were scattered throughout the extensive necrosis in the 131I-SFM-s-lipiodol group at 7 days post-embolization. The progressive changes in ears indicated that 223Ra-SFM-s-lipiodol TARE induced restricted and thorough damage, which resulted from the shorter radiation range and higher energy of α-particles than β-particles.

3.3 Distribution of SFMs-lipiodol in TARE

Because there was no γ radiation in the normal and the SFMs-lipiodol groups and a low dose of γ radiation in the 223Ra-SFM-s-lipiodol group, the 131I-SFM-s-lipiodol group was examined at 0 and 48 h after embolization. Because the same embolism procedure was used in other groups, except for the radionuclides, planar imaging of the 131I-SFM-s-lipiodol group revealed the distribution of embolism in all groups. Compared with the surrounding tissue, an embolism in the tip of the ear was distinguishable in the 131I-SFM-s-lipiodol group after injection, as presented in Figure 4A. The anchored radioactivity in the ACAs increased to 60.21% embolized dosage (ED) after the primary distribution. At 48 h after embolization, the leaked 131I-SFM-s was distributed in vivo without a specific target, as shown in Figure 4B. Meanwhile, 16.37% of the SFMs-lipiodol was excreted from the rabbit. Illustrated data visually demonstrated that 131I-SFM-s-lipiodol deposited in the ACA and provided continuous radiation to the ACA and its surroundings. Images confirmed that SFMs-lipiodol could potentially be used as the base of TARE.

In terms of quantification, ear-to-whole-body radioactivity ratios were maintained at a high level (60%–70%) at 0, 36, 72, and 120 h (Figure 4C). Results confirmed 131I-SFM-s-lipiodol demonstrated occlusion in the ACA and had a favorable in vivo distribution. The residual radioactivity ratio of decay-corrected embolization decreased between 72 and 120 h (Figure 4D), consistent with the timeline of extensive necrosis in 131I-SFM-s-lipiodol group shown in Figure 3.
3.4 The inhibition of neovascularization

To explore the influence of embolization on neovascularization, $^{68}$Ga-DOTA-RGD PET/CT was conducted at 4 days post-embolization. The uptake of $^{68}$Ga-DOTA-RGD was at the highest level in the SFMs-lipiodol group ($SUV_{\text{max}} = 0.240 \pm 0.040$), confirming the inductive effect of embolization; the $SUV_{\text{max}}$ of $^{68}$Ga-DOTA-RGD PET/CT in the normal group was $0.099 \pm 0.036$. In comparison, Figure 5 displayed that the tracer uptake increased in the ACA in the $^{131}$I-SFMs-lipiodol group ($SUV_{\text{max}} = 0.141 \pm 0.026$), which indicated that new blood vessels or a new blood supply existed. In contrast, the uptake of $^{68}$Ga-DOTA-RGD in the $^{223}$Ra-SFMs-lipiodol group was at a low level ($SUV_{\text{max}} = 0.053 \pm 0.004$), even lower than the normal group, manifesting a strong inhibition on neovascularization, which contributed to the accelerated necrosis shown in Figure 3. The results of $^{68}$Ga-DOTA-RGD PET/CT in each group were consistent with changes in the appearance of the rabbit ears.
3.5 The destruction of embolized vessels

3.5.1 H&E staining

The longitudinal sections of ACAs stained by H&E are displayed in Figure 6. In the normal group (Figure 6A), vascular endothelial cells and vascular smooth muscle cells were arranged in regular order. In Figure 6B, SFMs-lipiodol is indicated by black arrows in the lumen of the ACA at 7 days post-embolization. The SFMs-lipiodol group showed signs of moderate inflammation, indicating the post-treatment inflammatory cells, such as neutrophils and lymphocytes in the inside tissue of the vascular wall, which are indicated by a white arrow.

The organization structure of the vascular wall was changed in the H&E stained sections of the 223Ra-SFMs-lipiodol group (Figure 6D). In addition, nuclear atrophy and acidophilic bodies were found throughout the adjacent vascular tissues (white arrows). The majority of cell fragments were next to the lining of blood vessels (yellow arrows), and many nuclei disappeared in the lumen of the ACA (black arrows). Compared with the 131I-SFMs-lipiodol group (Figure 6C), the rupture of the blood vessel wall was more distinct and thorough, and the normal vascular structures were difficult to discern in the 223Ra-SFMs-lipiodol group. The existence of intercellular space is indicated by blue arrows in Figure 6D, and some platelets entered the inner vessel wall, manifesting that Ra-223 could break the intercellular space.

3.5.2 TUNEL staining

Only small amounts of cell apoptosis existed in normal tissues (Figure 6E). As exhibited in Figures 6F–H, cell apoptosis was detected in the inside of the ACAs in embolization groups by TUNEL staining (hollow arrows). In comparison with the normal group, the positive apoptotic cells were confined to the vascular endothelium in the 223Ra-SFMs-lipiodol group, while the involved range of cell apoptosis was wider in the 131I-SFMs-lipiodol group.

4 Discussion

This research aimed to establish the α-based TARE, which was first proved effective in inhibiting the proliferation of tumorous cells and VSMCs. Because the ability to proliferate independently of signals from other cell types is a fundamental characteristic of tumor cells (Kenny and Bissell, 2007), the direct break of vessels was meaningful in cutting off the blood supply of tumorous tissues. Thus, α-based TARE was an alternative to treating HCC, especially for a tumor close to the distal blood vessel. Previous studies have confirmed that TARE is a safe technology with an objective response in phase 3 trials (Chauhan et al., 2018). The effect of TARE mainly relies on cutting the arterial supply and the radiation from radionuclides (Li et al., 2020). α particles have higher linear energy transfer than β particles (Lee et al., 2020). β particles require several hundred traversals through the nucleus to induce cell death, while less than ten α particles achieve the same efficacy (King et al., 2021). Compared to β particles, the high LET and short range mean that α radiation treatments are more suitable for small-volume or residual micro-tumors, potentially offering more efficient and specific killing of tumors and avoiding damage to surrounding normal cells. However, this shorter range limits the long-range “cross-fire” effect of α particles, which is advantageous in β particle therapies for large-volume tumors (Song et al., 2017). Hence, although there are great differences between the embolization influences of these two kinds of radionuclides, α particles have great potential as an alternative for personalized treatment, and the principle needs to be further explored.

This study preliminarily established a new direction of TARE on HCC treatment, titled α-based TARE. Although TARE was based on the hepatic artery embolization for unresectable HCC (Habib et al., 2015; Chen et al., 2022), the adjacent tissues of the hepatic artery need protection from scattered rays. In this consideration, Ra-223-based TARE, which has a short radiation range, could effectively kill the tumor and avoid radiation damage to the surrounding normal tissues. This research revealed that Ra-223-based TARE could lead to complete necrosis, and the properly confined radiation range minimized the occurrence of adverse effects. In addition, the short range of α particles makes it easier to carry out radiation protection even though the therapy nuclides have a relatively long half-life.

Most HCCs are highly vascularized. The upregulation of hypoxia-inducible factor proteins enhances the expression of proangiogenic factors, including vascular endothelial growth factor (VEGF), which promotes angiogenesis in HCC tumors (Morse et al., 2019). Consequently, inhibition of angiogenesis in tumors is expected to improve the effects of TARE treatment. The results of 68Ga-DOTA-RGD PET/CT indicated that new blood flow was gradually established to compensate for embolization in the 131I-SFMs-lipiodol group. When compared with the 131I-SFMs-lipiodol group, tracer uptake in the 223Ra-SFMs-lipiodol group was at a low level, even lower than the normal group (0.053 ± 0.004 vs. 0.099 ± 0.036, p < 0.01). These results showed that the Ra-223 radiation strongly inhibits angiogenesis, which is beneficial for patients with advanced HCC. 223Ra-SFMs-lipiodol could potentially inhibit the growth of a carcinoma and decrease the recurrence of the tumor.
Hence, the development of α-based TARE is of great significance, and α-emitting radionuclides are promising candidates for TARE with their short range of radiation and high-energy α-particles.

The destruction of embolized vessels was another finding in this research. According to the analysis of H&E and TUNEL staining slides, the Ra-233 α radionuclides could break the intercellular space. Currently, resistance to targeted chemotherapeutic agents poses a huge challenge (Ma et al., 2021). This feature of breaking the intercellular space is far-reaching not only for cutting the artery feeding the tumor but also for the release of a drug to surrounding tissues. Thus, the use of chemotherapeutic drugs in TAE may decline when integrated with α-based TARE. For instance, the development of α-emitting radionuclides TAE together with chemotherapy drugs Sorafenib is a win-win option for the design of drugs for HCC treatment. Synergistic therapy could achieve the desired effect for HCC patients.

Several known challenges limit the wide application of α nuclides in the clinic (Marcu et al., 2018). For example, several low-dose radiation treatments over an extended period can improve effectiveness and reduce radiation toxicity. However, α-emitters are relatively scarce and are typically produced on a strict schedule, and it is critical that the supply of radionuclides is able to meet the clinical trial demand. In addition, although Ra-223 has the ability to be imaged via SPECT, the relatively low activity of the administered nuclides and the long acquisition time for SPECT produce blurred images. It is to be hoped that improving the quality and quantity of radionuclide production, combined with increasingly available tools, will make α nuclides suitable for clinical use in the future.

In a word, α-based TARE has an application prospect for HCC therapy.

5 Conclusion

In this study, we primarily explored the effects of α-based TARE on the ACA as structural destruction of embolized vessels and inhibition of neovascularization. The embolization results of 223Ra-SFMs-lipiodol provided evidence for the therapeutic effects of α-based TARE and provided a reference for HCC treatments in the setting of a personalized TARE protocol.

References

Aghevlian, S., Boyle, A. J., and Reilly, R. M. (2017). Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α particles or auger electrons. Adv. Drug Deliv. Rev. 109, 102–118. doi:10.1016/j.addr.2015.12.003

Bruix, J., Reig, M., and Sherman, M. (2016). Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150, 835–853. doi:10.1053/j.gastro.2015.12.041

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.

Ethics statement

The animal study was reviewed and approved by the Ethics Committee of Naval Medical University.

Author contributions

QT, XIL, QB, and CZ were responsible for the conceptualization of the study; RL, RW, and XIL were responsible for chemical synthesis; QT, RL, RW, YP, XIL, and SX carried out the animal studies; DL, GJ, YP, XiaL, and JY were responsible for data analysis and interpretation; XiaL, QB, and CZ provided the guidance and supervision for the execution of experiments; QT, RL, RW, and XIL prepared the draft of the manuscript. All the authors have read and agreed to the final version of the manuscript.

Funding

This work was funded by the National Natural Science Foundation of China (81960748 and 81871390).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Chamley-Campion, J., Campbell, G. R., and Ross, R. (1979). The smooth muscle cell in culture. *Physiol. Rev.* 59, 1–61. doi:10.1152/physrev.1979.59.1.1

Chauhan, N., Bukovcan, J., Boucher, E., Cosgrove, D., Edeline, J., Hamlyon, B., et al. (2018). Intra-arterial therasphere yttrium-90 glass microspheres in the treatment of patients with unresectable hepatocellular carcinoma: Protocol for the STOP-HCC phase 3 randomized controlled trial. *Invest. Radiol. Protoc.* 7, e11234. doi:10.1109/jrnl.2018.121236

Chen, H., Nan, G., Wei, D., Zhai, R. Y., Huang, M., Yang, W. W., et al. (2022). Hepatic artery injection of $^{90}Y$-metuximab combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A prospective nonrandomized, multicenter clinical trial. *J. Nucl. Med.* 63, 556–559. doi:10.2967/jnumed.121.262136

Clarke, L. P., Qadir, F., Al-Shibli, W., Sfakianakis, G., and Saffrin, A. N. (1983). Comparison of the physical characteristics of I-131 and I-123, with respect to differentiating the relative activity in the kidneys. *J. Nucl. Med.* 24, 683–688.

Edeline, J., Gilbert, M., Garin, E., Boucher, E., and Raoul, J. L. (2015). Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. *Liver Cancer* 4, 16–25. doi:10.1003/j00343878

Fujisawa, H. (2016). Observation of radioactive iodine ([131]I (131I)) in cropland soil after the Fukushima nuclear accident. *Sci. Total Environ.* 566–567, 1432–1439. doi:10.1016/j.scitotenv.2016.06.004

Habib, A., Desai, K., Hickey, R., Thornburg, B., Lewandowski, R., and Salem, R. (2015). Transarterial approaches to primary and secondary hepatic malignancies. *Nat. Rev. Clin. Oncol.* 12, 481–489. doi:10.1038/nrclinonc.2015.78

He, F., You, X., Gong, H., Yang, Y., Bai, T., Wang, W., et al. (2020). Stretchable, biocompatible, and multifunctional silk fibroin-based hydrogels toward wearable strain/pressure sensors and triboelectric nanogenerators. *ACS Appl. Mater. Interfaces* 12, 6442–6450. doi:10.1021/acsami.9b19721

Heskamp, S., Hernandez, R., Molkenboer-Kuenen, J. D. M., Essler, M., Bruchertseifer, F., Morgenstern, A., et al. (2017). α-versus β-emitting radionuclides for pretargeted radioimmunotherapy of carcinoembryonic antigen-expressing human colon cancer xenografts. *J. Nucl. Med.* 58, 926–933. doi:10.2967/jnumed.116.187021

Kenny, P. A., and Bissell, M. J. (2007). Targeting TACE-dependent EGFR ligand shedding in breast cancer. *J. Clin. Invest.* 117, 337–345. doi:10.1172/JCI29518

King, A. P., Lin, F. I., and Escorcio, F. E. (2021). Why bother with alpha particles? *Eur. J. Nucl. Med. Mol. Imaging* 49, 7–17. doi:10.1007/s00259-021-05431-y

Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R., et al. (2016). $^{90}$Y-DOTATOC receptor-targeted alpha-radioscopy therapy induces remission in neuroendocrine tumours refractory to beta radiation: A first-in-human experience. *Eur. J. Nucl. Med. Mol. Imaging* 41, 2106–2119. doi:10.1007/s00259-015-2857-9

Lee, H., Riad, A., Martorano, P., Mansfield, A., Samanta, M., Batra, V., et al. (2020). PARP-1-targeted auger emitters display high-LET cytotoxic properties in vitro but show limited therapeutic utility in solid tumor models of human neuroblastoma. *J. Nucl. Med.* 61, 850–856. doi:10.2967/jnumed.119.239865

Li, R., Li, D., Jia, G., Li, X., Sun, G., and Zuo, C. (2020). Diagnostic performance of therastronic radionuclides used in transarterial radioembolization for liver cancer. *Front. Oncol.* 10, 551622. doi:10.3389/fonc.2020.551622

Li, X., Ji, X., Chen, K., Ullah, M. W., Li, B., Cao, J., et al. (2021). Immobilized thrombin on X-ray radiopaque polyvinyl alcohol/chitosan embolic microspheres for precise localization and topical blood coagulation. *Bioact. Mat.* 6, 2105–2119. doi:10.1016/j.bioactmat.2020.12.013

Llovet, J. M., Kelly, R. K., Villanueva, A., Singal, A. G., Piksars, E., Rosayrie, S., et al. (2021). Hepatocellular carcinoma. *Nat. Rev. Dis. Prim.* 7, 6. doi:10.1038/s41572-020-00240-3

Ma, L., Xu, A., Kang, L., Cong, R., Fan, Z., Zhu, X., et al. (2021). LSD1-demethylated LIN28A2 confers oxaliplatin resistance through SP1-induced p62 transcription in HCC. *Hepatol. Therap.* 74, 3213–3234. doi:10.1016/j.jhep.32079

Marcu, L., Bezak, E., and Allen, B. J. (2018). Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. *Crit. Rev. Oncol. Hematol.* 123, 7–20. doi:10.1016/j.critrevonc.2018.01.001

Mies, G., Niebuhr, I., and Hossmann, K. A. (1981). Simultaneous measurement of blood flow and glucose metabolism by autoradiographic techniques. *Stroke* 12, 581–588. doi:10.1161/01.str.12.5.581

Morse, M. A., Sun, W., Kim, R., He, A. R., Abada, P. B., Mynderse, M., et al. (2019). The Role of angiogenesis in hepatocellular carcinoma. *Clin. Cancer Res.* 25, 912–920. doi:10.1158/1078-0432.CCR-18-1254

Pandit-Taskar, N., Larson, S. M., and Carrasquillo, J. A. (2014). Bone-seeking radiopharmaceuticals for treatment of osseous metastases, part 1: a therapy with $^{223}$Ra–dichloride. *J. Nucl. Med.* 55, 268–274. doi:10.2967/jnumed.114.1121482

Parihar, A. S., Mittal, B. R., Kumar, R., Shukla, J., and Bhattacharya, A. (2020). $^{90}$Y-DOTATOC-RGD2 positron emission tomography/computed tomography in radioiodine refractory thyroid cancer: Prospective comparison of diagnostic accuracy with $^{99}$mTc-positron emission tomography/computed tomography and evaluation toward potential potential theranostics. *Thyroid* 30, 557–567. doi:10.1089/thy.2019.0450

Reinders, M. T. M., Smits, M. L. J., van Roekel, C., and Braat, A. J. A. T. (2019). Holmium-166 microsphere radioembolization of hepatic malignancies. *Semin. Nucl. Med.* 49, 237–243. doi:10.1016/j.semnuclmed.2019.01.008

Roobol, S. J., Van den Bent, I., Van Cappellen, W. A., Abraham, T. E., Paul, M. W., Kanaar, R., et al. (2020). Comparison of high- and low-LET radiation-induced DNA double-strand break processing in living cells. *Int. J. Mol. Sci.* 21, 6602. doi:10.3390/ijms21266602

Sgouros, G. (2008). Alpha particles for targeted therapy. *Adv. Drug Deliv. Rev.* 60, 1402–1406. doi:10.1016/j.addr.2008.04.007

Song, G., Cheng, L., Chao, Y., Yang, K., and Liu, Z. (2017). Emerging nanotechnology and advanced materials for cancer radiation therapy. *Adv. Mat.* 29, 1700996. doi:10.1002/adma.201700996

Sun, G., Wang, T., Li, X., Li, D., Peng, Y., Wang, X., et al. (2018). Sub-micrometer Au@PDA-$^{111}$I particles as theranostic emboloma beads for radiosensitization and SPECT/CT monitoring. *Adv. Healthc. Mat.* 24, 683–688. doi:10.1002/adhm.201700375

Wu, X., Ge, L., Shen, G., He, Y., Xu, Z., Li, D., et al. (2022). $^{111}$I-labeled silk fibroin microspheres for radioembolic therapy of rat hepatocellular carcinoma. *ACS Appl. Mat. Interfaces* 14, 21848–21858. doi:10.1021/acsami.2c02111